SCHEMBL22657477

SCHEMBL22657477

O=CCc1c(F)cc(N2CCCCC2)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
KDM4E B2RXH2 2/20 0.41
IP6K1 Q92551 1/20 0.39
TRIM24 O15164 1/20 0.38
TRIM33 Q9UPN9 1/20 0.38
NPC1 O15118 5/20 0.36
RAB9A P51151 5/20 0.36
GFER P55789 2/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 5/20 0.34
HPGD P15428 3/20 0.34
TSHR P16473 2/20 0.34
NPSR1 Q6W5P4 2/20 0.33
TP53 P04637 1/20 0.33
MAPK1 P28482 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
GRK6 P43250 1/20 0.33
KMT2A Q03164 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22657531 0.98 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2KDM4EIP6K1TRIM24
SCHEMBL22657488 0.83 AKR1C3 (0.42) ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL22657713 0.77 IP6K1 (0.39) ALDH1A1SMN1; SMN2KDM4EIP6K1NPC1
SCHEMBL28704804 0.74 IP6K1 (0.40) ALDH1A1SMN1; SMN2KDM4EIP6K1NPC1
SCHEMBL18297686 0.74 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2KDM4EIP6K1TRIM24
SCHEMBL28838789 0.73 MAPT (0.41) ALDH1A1KDM4EIP6K1NPC1RAB9A
SCHEMBL30582917 0.72 HRH3 (0.46) ALDH1A1SMN1; SMN2KDM4E
SCHEMBL30582907 0.72 HRH3 (0.46) ALDH1A1SMN1; SMN2KDM4E
SCHEMBL6065386 0.72 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2KDM4ETRIM24TRIM33
SCHEMBL28123395 0.71 TSHR (0.42) ALDH1A1KDM4EIP6K1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof ALECTOS THERAPEUTICS 1NC (CA) 2026-04-28 US disclosed
EP-3966199-B1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC (CA) 2026-03-18 EP disclosed
CN-114174263-B Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2025-01-10 CN disclosed
US-20220213058-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2022-07-07 US disclosed
EP-3966199-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF Alectos Therapeutics Inc. (CA) 2022-03-16 EP disclosed
CN-114174263-A Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2022-03-11 CN disclosed
WO-2020229968-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2020-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213058-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF GBA1, GBA2, GAA ALDH1A1 3200/4885SMN1; SMN2 2285/4885KDM4E 2704/4885
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof GBA1, GBA2, MAN2B1 ALDH1A1 1393/4885SMN1; SMN2 2482/4885KDM4E 705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.